PL3345607T3 - Sposoby modyfikowania wzrostu kości poprzez podanie antagonisty lub agonisty sost lub wise - Google Patents

Sposoby modyfikowania wzrostu kości poprzez podanie antagonisty lub agonisty sost lub wise

Info

Publication number
PL3345607T3
PL3345607T3 PL18157578.8T PL18157578T PL3345607T3 PL 3345607 T3 PL3345607 T3 PL 3345607T3 PL 18157578 T PL18157578 T PL 18157578T PL 3345607 T3 PL3345607 T3 PL 3345607T3
Authority
PL
Poland
Prior art keywords
sost
agonist
administration
methods
bone growth
Prior art date
Application number
PL18157578.8T
Other languages
English (en)
Polish (pl)
Inventor
Debra L. Ellies
Original Assignee
Ossifi-Mab Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39584303&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3345607(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ossifi-Mab Llc filed Critical Ossifi-Mab Llc
Publication of PL3345607T3 publication Critical patent/PL3345607T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A61L2300/256—Antibodies, e.g. immunoglobulins, vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL18157578.8T 2006-12-29 2007-12-21 Sposoby modyfikowania wzrostu kości poprzez podanie antagonisty lub agonisty sost lub wise PL3345607T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88264206P 2006-12-29 2006-12-29

Publications (1)

Publication Number Publication Date
PL3345607T3 true PL3345607T3 (pl) 2023-01-09

Family

ID=39584303

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18157578.8T PL3345607T3 (pl) 2006-12-29 2007-12-21 Sposoby modyfikowania wzrostu kości poprzez podanie antagonisty lub agonisty sost lub wise

Country Status (12)

Country Link
US (8) US8178099B2 (enExample)
EP (3) EP2144613B1 (enExample)
JP (4) JP2010528002A (enExample)
DK (1) DK3345607T3 (enExample)
ES (2) ES2666650T3 (enExample)
FI (1) FI3345607T3 (enExample)
HU (1) HUE060822T2 (enExample)
LT (1) LT3345607T (enExample)
PL (1) PL3345607T3 (enExample)
PT (1) PT3345607T (enExample)
SI (1) SI3345607T1 (enExample)
WO (1) WO2009131553A2 (enExample)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX343200B (es) 1998-11-27 2016-10-19 Ucb Pharma Sa Composiciones y metodos para aumentar la mineralizacion ósea.
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
EP1636270B1 (en) 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
JP2008511420A (ja) 2004-08-30 2008-04-17 スピネオベイションズ・インコポレーテッド 脊髄の椎間板内障害の治療の方法
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
JP2010528002A (ja) * 2006-12-29 2010-08-19 オステオジェネックス インコーポレイテッド Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
BRPI0820387A2 (pt) * 2007-11-21 2015-05-26 Amgen Inc Agentes de ligação de wise e epítopos
US8469961B2 (en) * 2008-03-05 2013-06-25 Neville Alleyne Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints
WO2010115932A1 (en) * 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
US20130138221A1 (en) * 2010-04-16 2013-05-30 Novartis Ag Methods and compositions for improving implant osseointegration
SMT202000095T1 (it) 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
WO2012028683A1 (en) 2010-09-02 2012-03-08 Novartis Ag Antibody gel system for sustained drug delivery
JP2014509588A (ja) 2011-03-01 2014-04-21 アムジエン・インコーポレーテツド 二特異性結合剤
EP2688910B1 (en) 2011-03-25 2019-05-29 Amgen Inc. Anti-sclerostin antibody crystals and formulations thereof
JP6301832B2 (ja) 2011-08-04 2018-03-28 アムジエン・インコーポレーテツド 骨間隙欠陥を処置する方法
CN107126560A (zh) 2011-12-28 2017-09-05 安进公司 通过使用抗骨硬化蛋白抗体治疗牙槽骨流失的方法
CN104619342A (zh) 2012-07-05 2015-05-13 Ucb医药有限公司 骨疾病的治疗
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9770415B2 (en) * 2012-11-27 2017-09-26 Southwest Research Institute Delivery substrates from aligned polymer biomaterials for tissue repair
CN105073195A (zh) 2013-02-04 2015-11-18 昂科梅德制药有限公司 使用Wnt途径抑制剂进行治疗的方法及对该治疗的监测
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
JP2018505726A (ja) 2015-01-16 2018-03-01 スピネオベイションズ・インコーポレーテッド 脊椎円板を処置する方法
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN106202901A (zh) * 2016-07-04 2016-12-07 奥美之路(北京)健康科技股份有限公司 骨龄远程在线判读系统
JP2020502218A (ja) 2016-12-21 2020-01-23 メレオ バイオファーマ ３ リミテッド 骨形成不全症の処置における抗スクレロスチン抗体の使用
WO2019154410A1 (zh) * 2018-02-12 2019-08-15 翼高生物科技有限公司 针对骨硬化蛋白的适体及其用途
JP7405764B2 (ja) 2018-03-30 2023-12-26 アムジエン・インコーポレーテツド Ｃ末端抗体改変体
WO2020163290A1 (en) * 2019-02-04 2020-08-13 Emory University Sclerostin inhibitors that promote bone morphogenetic protein expression
US20220259298A1 (en) * 2019-07-12 2022-08-18 Kyoto University Neutralizing Antibody for Tooth Regeneration Treatment Targeting USAG-1 Molecule
CN111658821A (zh) * 2020-06-03 2020-09-15 深圳市百吉因生物科技有限公司 负载小干扰rna的胶原基骨修复材料及制备方法及在制备治疗骨质疏松骨折材料中的应用
WO2024250012A2 (en) 2023-06-02 2024-12-05 33 Medical, Inc. Compositions for treatment of discogenic pain, and processes for making and using the same

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6133117B2 (enExample) 1980-04-07 1986-07-31 Joeru Beruman Deii Bii Ei Joeru Beruman Asosheitsu
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3587956T2 (de) * 1984-04-30 1995-05-24 Procter & Gamble Ausrüstung für die Verwendung bei der Behandlung von Osteoporose.
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5324819A (en) 1988-04-08 1994-06-28 Stryker Corporation Osteogenic proteins
US5344654A (en) 1988-04-08 1994-09-06 Stryker Corporation Prosthetic devices having enhanced osteogenic properties
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5298852A (en) 1988-12-22 1994-03-29 Robert Bosch Gmbh Arrangement for and method of controlling a three-phase-generator in a vehicle
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5561173A (en) * 1990-06-19 1996-10-01 Carolyn M. Dry Self-repairing, reinforced matrix materials
KR100240308B1 (ko) 1991-03-06 2000-01-15 플레믹 크리스티안 인간화된단클론성항체및혼성단클론성항체
US5656593A (en) 1991-03-11 1997-08-12 Creative Biomolecules, Inc. Morphogen induced periodontal tissue regeneration
US5118667A (en) 1991-05-03 1992-06-02 Celtrix Pharmaceuticals, Inc. Bone growth factors and inhibitors of bone resorption for promoting bone formation
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
EP0612348B1 (en) 1991-11-04 2003-04-23 Genetics Institute, LLC Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
ZA931148B (en) 1992-02-19 1993-08-18 Schering Corp Cloning and expression of humanized monoclonal antibodies against human interfluekin-4.
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
IT1255522B (it) 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
DE69403439T2 (de) * 1993-01-12 1997-10-23 Genentech Inc Tgf-beta zusammensetzung zum herbeiführen von knochenwachstum
TW303299B (enExample) * 1993-07-22 1997-04-21 Lilly Co Eli
US5705154A (en) 1995-03-08 1998-01-06 Schering Corporation Humanized monoclonal antibodies against human interleukin-4
US5550134A (en) * 1995-05-10 1996-08-27 Eli Lilly And Company Methods for inhibiting bone loss
DE19647853A1 (de) * 1996-11-19 1998-05-20 Bioph Biotech Entw Pharm Gmbh Verbindungen mit verbesserter knorpel- und/oder knocheninduzierender Aktivität
US5939039A (en) 1997-01-16 1999-08-17 Orthovita, Inc. Methods for production of calcium phosphate
EP1350525A3 (en) 1997-02-07 2003-12-10 Stryker Corporation Matrix-free osteogenic devices, implants and methods thereof
US20020098222A1 (en) * 1997-03-13 2002-07-25 John F. Wironen Bone paste
US7041641B2 (en) * 1997-03-20 2006-05-09 Stryker Corporation Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects
DE69818456T2 (de) * 1997-04-22 2004-07-29 Washington Research Foundation, Seattle Knochentransplantate und -prothesen beschichtet mit tartratbeständiger säurephosphatase
US6025538A (en) 1998-11-20 2000-02-15 Musculoskeletal Transplant Foundation Compound bone structure fabricated from allograft tissue
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
MX343200B (es) * 1998-11-27 2016-10-19 Ucb Pharma Sa Composiciones y metodos para aumentar la mineralizacion ósea.
US6756480B2 (en) * 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
AU2002239965B2 (en) 2000-07-19 2007-01-04 Orthologic Corp. Stimulation of bone growth and cartilage formation with thrombing peptide derivatives
US20030082233A1 (en) 2000-12-01 2003-05-01 Lyons Karen M. Method and composition for modulating bone growth
WO2002067978A1 (en) 2001-02-23 2002-09-06 Wyeth Chondrogenic potential of human bone marrow-derived cd105+ cells by bmp
US6949251B2 (en) 2001-03-02 2005-09-27 Stryker Corporation Porous β-tricalcium phosphate granules for regeneration of bone tissue
BR0209563A (pt) 2001-05-11 2004-12-07 Genome Theraupeutics Corp ácido nucleico, polipeptìdeo, vetor, célula, anticorpo, métodos de diagnosticar um fenótipo e um paciente como expressando um ácido nucleico e de identificar agentes que modulam a atividade de um ácido nucleico e de uma proteìna e lrp5, lrp6, ou hbm e compostos que modulam a interação de dkk com o caminho de sinalização wnt, composição para modular a massa óssea e/ou os nìveis de lipìdeo em um paciente, animal transgênico, embrião e modelo de animal, e, agente
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
ES2675735T3 (es) * 2001-06-26 2018-07-12 Amgen Inc. Anticuerpos para OPGL
US7157096B2 (en) 2001-10-12 2007-01-02 Inframat Corporation Coatings, coated articles and methods of manufacture thereof
EP1446114A4 (en) 2001-11-08 2005-05-25 Merck & Co Inc COMPOSITIONS AND METHODS FOR TREATING OSTEOPOROSIS
US7015195B2 (en) * 2002-01-10 2006-03-21 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
JP3646167B2 (ja) 2002-02-19 2005-05-11 独立行政法人産業技術総合研究所 フォスフォフォリンを含む複合生体材料
AU2003223214B2 (en) 2002-03-01 2008-09-18 Celltech R & D, Inc. Methods to increase or decrease bone density
US7166133B2 (en) * 2002-06-13 2007-01-23 Kensey Nash Corporation Devices and methods for treating defects in the tissue of a living being
US7585501B2 (en) 2002-06-14 2009-09-08 Stowers Institute For Medical Research Compositions and methods for treating kidney disease
AU2003276430A1 (en) * 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
US7893218B2 (en) 2003-06-16 2011-02-22 Stowers Institute For Medical Research Antibodies that specifically bind SOST peptides
US20040002770A1 (en) 2002-06-28 2004-01-01 King Richard S. Polymer-bioceramic composite for orthopaedic applications and method of manufacture thereof
EP1539239A4 (en) * 2002-07-02 2005-09-14 Smithkline Beecham Corp NEW STABLE FORMULATION
US20040023322A1 (en) * 2002-08-01 2004-02-05 Goodheart Clyde R. Method of producing non-recombinant BMP-2 and use thereof
KR20040023356A (ko) 2002-09-11 2004-03-18 현대모비스 주식회사 파킹브레이크 작동시 출발제한 시스템 및 그 방법
JP2006503615A (ja) 2002-09-30 2006-02-02 リージェン バイオテック インコーポレーテッド 硫酸カルシウム及び粘性を有するポリマーを含む骨形成および骨硬化を促進させる骨充填用組成物
JP3851602B2 (ja) * 2002-10-02 2006-11-29 ペンタックス株式会社 骨形成治療デバイス
BRPI0411020A (pt) 2003-06-06 2006-07-18 Wyeth Corp perfil de expressão de gene, métodos de identificar agentes modulares do caminho de wnt, de preparar um perfil de expressão de gene, de triar um agente que realce a remodelagem associada com a carga óssea e reagentes que se ligam às proteìnas que modulam a remodelagem óssea e/ou mineralização óssea, de tratar uma doença ou distúrbio de mineralização óssea, de modular a mineralização óssea em uma célula e a mineralização óssea e/ou remodelagem óssea em um paciente e de determinar se um composto ou uma composição realçam o efeito de carga óssea na atividade/função e/ou mineralização da célula óssea, agente candidato para tratar uma condição de massa óssea baixa e composição
EP1636270B1 (en) 2003-06-16 2016-07-20 UCB Pharma S.A. Antibodies specific for sclerostin and methods for increasing bone mineralization
US7943393B2 (en) 2003-07-14 2011-05-17 Phynexus, Inc. Method and device for extracting an analyte
US6976816B2 (en) 2003-08-01 2005-12-20 Dana Corporation Combination lock washer and spindle bearing assembly
MY141763A (en) * 2003-09-18 2010-06-30 Novartis Ag Pharmaceutical products comprising bisphosphonates
US8461155B2 (en) 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
WO2005070439A1 (en) * 2004-01-09 2005-08-04 Regeneration Technologies Inc. Implant comprising a human muscle tissue matrix
US7189263B2 (en) 2004-02-03 2007-03-13 Vita Special Purpose Corporation Biocompatible bone graft material
US7531518B2 (en) 2004-05-14 2009-05-12 Unigene Laboratories Inc. Method for fostering bone formation and preservation
US7648965B2 (en) 2004-05-14 2010-01-19 Unigene Laboratories Inc. Method for fostering bone formation and preservation
WO2005118636A2 (en) * 2004-05-27 2005-12-15 Acceleron Pharma Inc. Tgf derepressors and uses related thereto
JP4840939B2 (ja) 2004-08-04 2011-12-21 アムジェン インコーポレイテッド Ｄｋｋ−１に対する抗体
WO2006047310A2 (en) * 2004-10-22 2006-05-04 The Board Of Trustees Of The University Of Illinois Hollow and porous orthopaedic or dental implant that delivers a biological agent
SG161218A1 (en) * 2005-01-06 2010-05-27 Kuros Biosurgery Ag Supplemented matrices for the repair of bone fractures
US7531533B2 (en) * 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
US8071574B2 (en) 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
US20060198863A1 (en) 2005-03-03 2006-09-07 Musculoskeletal Transplant Foundation Ceramic composition for filling bone defects
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
JP2006320442A (ja) 2005-05-18 2006-11-30 Toshiba Ceramics Co Ltd リン酸カルシウム系骨補填材
US20060293667A1 (en) 2005-05-19 2006-12-28 Agnes Vignery Bone implant device and methods of using same
WO2006135734A2 (en) 2005-06-10 2006-12-21 The Regents Of The University Of California Compositions and methods for altering bone density and bone patterning
BRPI0611800A2 (pt) * 2005-06-15 2008-12-09 Schering Corp formulaÇço estÁvel de anticorpo
CN103349793B (zh) 2005-09-09 2016-02-10 阿格诺沃斯健康关爱公司 复合骨移植替代物水泥以及由其制得的制品
CA2630077C (en) 2005-11-17 2014-07-15 Biomimetic Therapeutics, Inc. Maxillofacial bone augmentation using rhpdgf-bb and a biocompatible matrix
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
BRPI0620316A2 (pt) 2005-12-21 2011-11-08 Wyeth Corp formulações de proteìnas com viscosidades reduzida e seus usos
US20100015665A1 (en) * 2006-11-10 2010-01-21 Ucb Pharma S.A. Antibodies and diagnostics
JP2010528002A (ja) 2006-12-29 2010-08-19 オステオジェネックス インコーポレイテッド Ｓｏｓｔもしくはｗｉｓｅアンタゴニストまたはアゴニストの投与による骨成長を変化させる方法
BRPI0809026A2 (pt) 2007-03-20 2014-09-23 Lilly Co Eli Anticorpos antiesclerotina
WO2008133618A1 (en) 2007-04-27 2008-11-06 Unigene Laboratories, Inc. Methods and compositions for fostering and preserving bone growth
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
TWI629355B (zh) * 2010-11-17 2018-07-11 中外製藥股份有限公司 具有替代血液凝固第ｖｉｉｉ因子之功能的多重專一性抗原結合分子
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
JP6511233B2 (ja) 2014-08-28 2019-05-15 株式会社竹中工務店 柱脚部と鉄骨梁との接合構造

Also Published As

Publication number Publication date
US20150086571A1 (en) 2015-03-26
EP3345607B1 (en) 2022-10-26
FI3345607T3 (fi) 2022-11-30
SI3345607T1 (sl) 2023-03-31
HUE060822T2 (hu) 2023-04-28
US20170044248A1 (en) 2017-02-16
US20240360207A1 (en) 2024-10-31
ES2930183T3 (es) 2022-12-07
US8178099B2 (en) 2012-05-15
DK3345607T3 (da) 2022-11-21
US11891438B2 (en) 2024-02-06
US20130195856A1 (en) 2013-08-01
WO2009131553A2 (en) 2009-10-29
ES2666650T3 (es) 2018-05-07
JP2017014263A (ja) 2017-01-19
EP2144613B1 (en) 2018-03-21
US11807681B2 (en) 2023-11-07
US20230357377A1 (en) 2023-11-09
US11608373B2 (en) 2023-03-21
EP4176884A1 (en) 2023-05-10
US8877196B2 (en) 2014-11-04
LT3345607T (lt) 2023-01-10
JP2014074046A (ja) 2014-04-24
EP2144613A2 (en) 2010-01-20
US20080160060A1 (en) 2008-07-03
PT3345607T (pt) 2022-11-21
US20230226086A1 (en) 2023-07-20
EP3345607A1 (en) 2018-07-11
JP2010528002A (ja) 2010-08-19
JP2018199725A (ja) 2018-12-20
WO2009131553A3 (en) 2010-04-29
US20120201815A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
LT3345607T (lt) Kaulų augimo keitimo būdai, skiriant sost arba wise antagonistą ar agonistą
HUS000509I2 (hu) Abemaciklib vagy egy gyógyászatilag elfogadható sója
IL196181A0 (en) Substituted n-phenylmethyl-5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
ZA200904446B (en) Methods of use for cyclopamine analogs
EP1996125A4 (en) GLENOID ELEMENT WITH ENHANCED FASTENING STABILITY
ZA201106538B (en) Compositions and methods for increasing muscle growth
IL194862A0 (en) Maleate co-crystal of azd1152
IL196706A0 (en) Crystalline forms of rapamycin analogs
AP2008004406A0 (en) Methods of managing timberland
ZA200808245B (en) Compositions and methods for inducing bone growth and inhibiting bone loss
GB0705854D0 (en) Methods of construction
IL206479A0 (en) Crystalline forms of palonosetron hydrochloride
AP2784A (en) Methods of managing timberland
ZA200806508B (en) Salt of CD80 Antagonist
IL196320A0 (en) Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
IL197192A0 (en) Preparation of decahalodiphenyl ethane
ZA200810726B (en) Substituted N-Phenylmethyl -5-OXO-Proline-2-Amides AS P2X7-Receptor Antagonists and their methods of use
ZA201108374B (en) Methods of administration of thrombopoietin agonist compounds
ZA200900740B (en) Crystalline forms of rapamycin analogs
EG24395A (en) New method for depittering of apricot seed
ZA200900669B (en) Spinal prosthesis with offset anchors
GB0601140D0 (en) Tissue monitor
AU2007902502A0 (en) Game fishing chair
GB0604819D0 (en) Methods of analysing cell growth behaviour
HK1175109A (en) Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof